EA201790651A2 - Способ лечения рака и инфаркта миокарда - Google Patents

Способ лечения рака и инфаркта миокарда

Info

Publication number
EA201790651A2
EA201790651A2 EA201790651A EA201790651A EA201790651A2 EA 201790651 A2 EA201790651 A2 EA 201790651A2 EA 201790651 A EA201790651 A EA 201790651A EA 201790651 A EA201790651 A EA 201790651A EA 201790651 A2 EA201790651 A2 EA 201790651A2
Authority
EA
Eurasian Patent Office
Prior art keywords
myocardial infarction
treating cancer
sensitivity
compound
formula
Prior art date
Application number
EA201790651A
Other languages
English (en)
Other versions
EA201790651A3 (ru
EA031090B1 (ru
Inventor
Мин Чу Сюй
Ин-Хуэй Хуан
Чи-Фэн Янь
Чи-Синь Ричард Цзин
Original Assignee
Тайджен Байотекнолоджи Ко. Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тайджен Байотекнолоджи Ко. Лтд. filed Critical Тайджен Байотекнолоджи Ко. Лтд.
Publication of EA201790651A2 publication Critical patent/EA201790651A2/ru
Publication of EA201790651A3 publication Critical patent/EA201790651A3/ru
Publication of EA031090B1 publication Critical patent/EA031090B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

Способ повышения чувствительности раковой клетки к химиотерапевтическому препарату или отслеживания инфаркта миокарда. Способ включает введение объекту, нуждающемуся в этом, эффективного количества соединения формулы (I)где Rпредставляет собой Cциклоалкил, каждый Rпредставляет собой Н или Cалкил, Lпредставляет собой Cгетероциклоалкил, Lпредставляет собой Cциклоалкил и каждый из m, n, o, р и q независимо составляет от 0 до 6.
EA201790651A 2014-09-30 2015-06-02 Способ лечения рака и инфаркта миокарда EA031090B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14/502,144 US9375406B2 (en) 2014-09-30 2014-09-30 Substituted pyrimidines for mobilizing cells expressing a type 4 CXC chemokine receptor
PCT/US2015/033723 WO2016053392A2 (en) 2014-09-30 2015-06-02 Method of treating cancer and myocardial infarction

Publications (3)

Publication Number Publication Date
EA201790651A2 true EA201790651A2 (ru) 2017-08-31
EA201790651A3 EA201790651A3 (ru) 2017-12-29
EA031090B1 EA031090B1 (ru) 2018-11-30

Family

ID=55583732

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201790651A EA031090B1 (ru) 2014-09-30 2015-06-02 Способ лечения рака и инфаркта миокарда

Country Status (9)

Country Link
US (1) US9375406B2 (ru)
EP (2) EP4438116A2 (ru)
JP (2) JP6581654B2 (ru)
KR (2) KR20230149325A (ru)
CN (2) CN107427513A (ru)
EA (1) EA031090B1 (ru)
HK (1) HK1247817A1 (ru)
TW (1) TWI666216B (ru)
WO (1) WO2016053392A2 (ru)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085196A2 (en) * 2000-05-09 2001-11-15 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US20030199464A1 (en) * 2002-04-23 2003-10-23 Silviu Itescu Regeneration of endogenous myocardial tissue by induction of neovascularization
WO2005002522A2 (en) * 2003-06-30 2005-01-13 Caritas St. Elizabeth's Medical Center Of Boston, Inc. Compositions and methods for treating tissue ischemia
WO2006138304A2 (en) * 2005-06-14 2006-12-28 Taigen Biotechnology Pyrimidine compounds
CN101242848B (zh) * 2005-06-14 2011-12-21 太景生物科技股份有限公司 嘧啶化合物
JP5217438B2 (ja) * 2005-11-18 2013-06-19 小野薬品工業株式会社 塩基性基を含有する化合物およびその用途
AR059197A1 (es) * 2006-01-25 2008-03-19 Smithkline Beecham Corp Derivados de indazolo piridina para el tratamiento de hiv
ES2545731T3 (es) * 2008-04-21 2015-09-15 Taigen Biotechnology Co., Ltd. Compuestos heterocíclicos
US9023834B2 (en) * 2008-11-13 2015-05-05 Taigen Biotechnology Co., Ltd. Lyophilization formulation
CN102058547A (zh) * 2009-11-12 2011-05-18 太景生物科技股份有限公司 冻干制剂
US10813917B2 (en) * 2009-12-11 2020-10-27 Medregen, Llc Treatment methods utilizing stem cell mobilizers and immunosuppressive agents
US20110207814A1 (en) * 2009-12-23 2011-08-25 Pranela Rameshwar Combination Therapy for Breast Cancer Treatment
US20140219952A1 (en) * 2010-03-23 2014-08-07 The Johns Hopkins University Methods of treatment using stem cell mobilizers
EP2648727A4 (en) * 2010-12-07 2014-05-07 Univ Johns Hopkins COMPOSITIONS AND METHODS FOR MOBILIZING STEM CELLS
JP2014513727A (ja) * 2011-05-16 2014-06-05 ジェンザイム・コーポレーション Ｃｘｃｒ４拮抗薬の使用

Also Published As

Publication number Publication date
KR20230149325A (ko) 2023-10-26
EP4438116A2 (en) 2024-10-02
EP3200796A4 (en) 2020-07-29
HK1247817A1 (zh) 2018-10-05
JP6844870B2 (ja) 2021-03-17
US20160090394A1 (en) 2016-03-31
EP3200796A2 (en) 2017-08-09
CN107427513A (zh) 2017-12-01
CN117503781A (zh) 2024-02-06
KR20170063763A (ko) 2017-06-08
TW201612186A (en) 2016-04-01
JP6581654B2 (ja) 2019-09-25
TWI666216B (zh) 2019-07-21
KR102589811B1 (ko) 2023-10-16
WO2016053392A9 (en) 2017-05-26
EP3200796B1 (en) 2024-08-07
JP2017530170A (ja) 2017-10-12
US9375406B2 (en) 2016-06-28
JP2019218383A (ja) 2019-12-26
WO2016053392A2 (en) 2016-04-07
EA201790651A3 (ru) 2017-12-29
EA031090B1 (ru) 2018-11-30

Similar Documents

Publication Publication Date Title
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CL2015002194A1 (es) Inhbidores de erk y sus usos
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
EA201792205A1 (ru) Гетероциклические соединения как ингибиторы lsd1
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201600622A1 (ru) Бициклические анелированные гетероарильные или арильные соединения и их применение в качестве ингибиторов irak4
EA201692079A1 (ru) Ингибиторы лизин-специфической деметилазы-1
PH12016500055A1 (en) N,6-bis(aryl or heteroaryl)-1,3,5-triazine-2,4-diamine compounds as idh2 mutants inhibitors for the treatment of cancer
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201691421A1 (ru) Гетероарилы и их применение
EA201690753A1 (ru) Комбинации ингибиторов гистондеацетилазы и иммуномодулирующих лекарственных средств
EA201990044A1 (ru) Гетероциклические соединения в качестве антибактериальных средств
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
EA201691472A1 (ru) Конденсированные пиримидины в качестве ингибиторов комплекса p97
CL2015002897A1 (es) Inhibidores de bace1
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
EA201592108A1 (ru) Гетероциклические соединения в качестве ингибиторов сигнального пути hedgehog
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
EA201792287A1 (ru) Способы лечения рака
EA201792096A2 (ru) РАППγ АГОНИСТЫ ДЛЯ ЛЕЧЕНИЯ РАССЕЯННОГО СКЛЕРОЗА
EA201500821A1 (ru) Производные 2-замещенных-6-биарилметиламино-9-циклопентил-9н-пуринов, их использование в качестве лекарственных средств и фармацевтических составов

Legal Events

Date Code Title Description
PC4A Registration of transfer of a eurasian patent by assignment